Podcasts about zepbound

You've done the meal prep, the steps, the Peloton rides after bedtime stories—yet the scale is not "scaling". Now everybody from your group chat to Serena Williams is talking about “the shot.” In this episode, Dr. Stephane Hack, MD, MPH, breaks down GLP-1 medications (like Ozempic, Wegovy, and Zepbound) in plain language: what they are, how they work, who they're really for, and what risks often get glossed over. We'll talk motherhood, metabolism, perimenopause, endometriosis, fertility, and the pressure to “snap back". Whether you're a busy professional juggling work, marriage, kids, or just trying to feel at home in your own body again, this conversation is your judgment-free zone to get informed before you decide what's next for your body.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor dive into your burning questions from around the world—exploring misunderstood metabolic problems, hard-won solutions for real people, and the science behind the headlines. From “selfish brain” physiology to the rollercoaster of insurance and medication access, Dr. Cooper brings clinical clarity and practical hope.Hear real-world listener stories, get advice on tuning your metabolic health, and learn why personalization—not “calories in, calories out”—leads to better outcomes. This is no silver bullet show: it's metabolic medicine, mythbusting, and science-backed encouragement for your journey.Key Questions AnsweredWhat is the “selfish brain” and how does it really impact blood sugar and diabetes risk?Why do GLP-1 medications affect stamina and hunger, and how should you fuel your body if you're using them?If insurance pulls coverage for medications like Ozempic or Zepbound, what are your practical, safe, and affordable options?How do metabolic markers, medication “cocktails,” and genetic testing shape Dr. Cooper's individualized care—and can you taper off meds and maintain results?What does “normal” blood sugar look like after meals, and how do you distinguish trends from outliers?Key TakeawaysMetabolism is complex—individualized care is essential. Diabetes, hypoglycemia, and insulin resistance all have personal causes and require testing like the Mixed Meal Tolerance Test to solve—not one-size-fits-all advice. GLP-1s require smart fueling. Many experience reduced stamina on these medications. Dr. Cooper recommends upping both complex and simple carbs pre-exercise and consulting with a registered dietitian if fatigue persists. Insurance coverage is a challenge—but not the end. Generic options (like liraglutide/Victoza via Mark Cuban Cost Plus Drugs), manufacturer programs, and “cocktail” regimens can support continued progress, even if you lose access to top-brand GLP-1s. Feedback loops & genetics drive lasting outcomes. While some patients can successfully—slowly—taper medications, most with metabolic dysfunction will need long-term support. “Clean eating” alone rarely reverses underlying feedback loop glitches. Monitoring is powerful. Using blood sugar monitors (especially for diabetics) can demystify meal spikes and help fine-tune nutrition and medication timing. Personal stories reflect broader truths. Listeners share struggles and solutions, reinforcing that metabolic health spans medication, motivation, and mindset.Dr. Cooper's Actionable TipsAlways dig deeper with testing—not just A1C but also post-meal spikes via the Mixed Meal Tolerance Test.If you're prescribed a GLP-1 and struggle with energy, increase carb intake safely and talk to a doctor about medication adjustment. For lost coverage, stick to FDA-approved sources: Lilly Direct for Zepbound, Novocare for Wegovy, and Mark Cuban for generics. Don't risk unregulated online compounds. Recognize the difference between generalized “healthy” habits and targeted strategies that actually move your biomarkers.Stay consistent and compassionate—focus on small improvements over extremes and absolutes.Notable Quote“The metabolism is regulated by a feedback loop…when you introduce outside hormone forms, you strengthen signals to favor fuel utilization over energy conservation.”— Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramGeneric medication access: Mark Cuban Cost Plus DrugsZepbound direct: Lilly DirectAdditional info: Novocare for WegovyFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

Welcome to Ozempic Weightloss Unlocked, where we decode the latest breakthroughs, news, and hidden truths about one of the world's most talked-about weight loss drugs. Today, the buzz is about change—how new research, fresh delivery methods, and evolving regulations are reshaping the Ozempic story. Let us start with what is most recent. There is a big development: needles may no longer be necessary. According to reporting in Popular Mechanics and new data published in The New England Journal of Medicine, Novo Nordisk, the maker of Ozempic and Wegovy, has released results for a daily oral version of semaglutide, the active ingredient in Ozempic. In their clinical trial, this pill matched the weight loss produced by the weekly injection, with an average of 16.6 percent reduction in body weight. About a third of participants lost more than 20 percent. While side effects like nausea and vomiting were reported at higher rates than placebo, this new pill could make using these drugs more accessible than ever.Access is also the hot topic in pricing. Until this year, monthly Ozempic prescriptions could cost up to $1,350 without insurance support. But after new negotiations, many users will soon pay $50 to $350 per month, depending on dosage and coverage. Lower prices are expected to make these drugs far more widely available.So, how well does Ozempic stack up in its primary role? Ozempic was first approved to treat type two diabetes, with weight loss as a major secondary effect. Harper Clinic Utah reports that, in clinical trials, people using Ozempic lost on average between 10 and 15 percent of their body weight over a little more than a year. But real world success depends on how consistently people use it and whether they also improve their diet and exercise habits.Now a common question—how does Ozempic compare to newer weight loss options like Zepbound and Wegovy? The main distinction is the active ingredient. Ozempic uses semaglutide, which triggers the body to release the hormone GLP-1, helping you feel fuller and slow digestion. Zepbound uses tirzepatide, which mimics both GLP-1 and a second hormone called GIP, and results from major trials suggest it can lead to more dramatic weight loss—up to 21 percent of body weight in some studies. However, Ozempic remains covered by insurance for diabetes, while Zepbound is less often covered.Beyond weight, a new area of research is exploring how Ozempic could affect long-term health conditions. According to ScienceDaily, a recent large-scale analysis found that when people stop using prescription weight loss drugs like Ozempic, they tend to regain much of their lost weight, underscoring the need for ongoing treatment or lifestyle change. But these medicines may do much more than affect weight. Recent studies at University of California San Diego found that people with colon cancer who were on GLP-1 drugs were less than half as likely to die within five years. Another new UVA study, covered by Fox News and ScienceDaily, points to dramatically lower death rates in cancer patients who use GLP-1 drugs like Ozempic—potentially because they lower inflammation and improve metabolic health.There is also new investigation about Ozempic's possible use in treating long COVID. According to research covered by ClickOnDetroit, anecdotal reports suggest that some people taking GLP-1 drugs for weight loss also experienced improvement in their post-COVID symptoms, and new clinical trials are underway.Despite these major advances, affordability and access remain challenges. The latest KFF Health Tracking Poll says that about one in eight adults in the United States are now taking a GLP-1 medication like Ozempic, Wegovy, or Zepbound. But half of those surveyed still find the drugs financially out of reach, even as prices are starting to come down.What does all this mean for lifestyle and health? The current scientific consensus is clear: these drugs do not replace needed changes in eating habits and physical activity. As physicians emphasize, Ozempic works best as part of a treatment plan that includes real lifestyle change.As you can see, Ozempic and drugs like it are not just a story about slimming down—they are opening doors to better health, new medical research, and greater access for millions. Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you do not miss the next episode covering the evolving science and your questions about Ozempic and weight loss. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In the past week, breakthrough developments surrounding Ozempic and its use for weight loss have dominated health news, reflecting sweeping changes in both medical access and public perception. According to Popular Mechanics, Novo Nordisk, the pharmaceutical giant behind Ozempic and the similar injectable Wegovy, has just revealed the results of a major 71-week clinical study evaluating an oral pill form of semaglutide, the active ingredient in both Ozempic and Wegovy. This study, published in The New England Journal of Medicine, found that the daily pill achieved nearly the same results as the weekly injection, with participants losing an average of 16.6 percent of their body weight, far surpassing the 2.7 percent weight loss seen in the placebo group. About one third of those taking the pill lost more than 20 percent of their starting weight, signaling not just statistical significance but profound clinical impact. The trial also reported side effects consistent with earlier injectable versions, including increased incidences of nausea and vomiting, though these were not severe enough to derail the optimism surrounding the pill's future.Compounding these scientific advancements, the White House this week announced successful negotiations with both Eli Lilly and Novo Nordisk to dramatically reduce the cost of GLP-1 receptor agonists—the drug class of Ozempic, Wegovy, and Zepbound—which many insurance providers had previously excluded or charged full price for. Now, eligible patients may see their out-of-pocket costs plummet from over one thousand dollars per month to a much more accessible fifty to three hundred fifty dollars depending on dosage and coverage. According to comments from Kim Fisher at the UC Davis Innovation Institute for Food and Health, these price adjustments are expected to drive a swift increase in demand and medication use, with around one in eight adult Americans having already tried some form of GLP-1 therapy.Despite the popularity and transformative outcomes touted by both consumers and medical professionals, Ozempic and related drugs are not without controversy. While these medications have reshaped the landscape for obesity and diabetes treatment, as UC Davis reports, emerging evidence indicates a need for caution and individualized care. Some patients experience notable gastrointestinal effects such as nausea and diarrhea, largely because GLP-1 drugs alter how the gut processes food and signal fullness to the brain. In addition, while fat loss can be dramatic, experts highlight that up to one quarter of the total weight lost may be from lean muscle, underscoring the importance of physical activity and adequate protein to preserve strength. Another concern echoed this week involves bone health, as rapid weight loss and restricted nutrition may inadvertently reduce bone density, especially in older adults and postmenopausal women. Leading researchers emphasize that a successful and safe weight loss journey with Ozempic demands precision nutrition, attentive exercise regimens, and regular monitoring to minimize health risks and maximize wellbeing.The intersection of celebrity culture with the Ozempic phenomenon also drew fresh attention over the past week, especially regarding Oprah Winfrey's evolving relationship with the drug. Oprah, who has long shared her struggles with weight publicly, admitted in recent interviews that she initially resisted taking Ozempic, saying she felt it was the easy way out and preferred to focus on lifestyle change. According to AOL, she reflected on her internal conflict about using medical intervention for weight loss, underscoring how the rise of drugs like Ozempic has forced a cultural reckoning over what constitutes effort, discipline, and legitimacy in personal health. While some celebrity peers openly dismiss rumors or deny any use of weight loss drugs, Oprah's decision to speak candidly about her hesitation and subsequent experiences gives voice to a wider conversation happening both in Hollywood and across the nation. As more public figures reveal their choices, the stigma of using medication to address chronic weight struggles may begin to dissipate, helping others seek support without shame.In summary, the past week has marked a pivotal moment in the ongoing Ozempic story. The introduction of a highly effective oral pill, substantial price cuts via government negotiation, and ongoing public debate about safety, efficacy, and cultural perceptions have all contributed to growing momentum. Now, as clinicians and patients alike look ahead to a future where advanced weight management tools are both more accessible and potentially safer to use, the importance of personalized guidance and health literacy has never been clearer.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.Background reading: How Ozempic's maker lost its shine after creating a wonder drug.What Trump's new drug pricing deal means for people with obesity.Photo: Sergei Gapon/Agence France-Presse — Getty ImagesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

In Part 1 we looked at the basics and early research around GLP-1s for weight loss and muscle loss. In part 2 we looked at recent research around the newest GLP-1 weight loss drugs, tirzepatide (Zepbound) and semaglutide (Wegovy).In this final part of the series we are going to talk about the justifications/excuses/spin that are happening around the loss of lean muscle mass on GLP-1s. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

One of biopharma's most memorable bidding wars finally came to an end on Friday—with Metsera right back in the arms of its original suitor, but with Pfizer paying around $10 billion for the rights to the obesity biotech, a nearly $3 billion increase over its original bid. But while Novo Nordisk may have bowed out of that race, the company still made headlines this past week, with CEO Maziar Mike Doustdar joining Eli Lilly head David Ricks at the White House on Thursday to announce a deal that will see their GLP-1 drugs offered at about $350 per month.   This marks a significant discount to the current list prices of $1086 and $1350 for Lilly's obesity drug Zepbound and Novo's comparator Wegovy, respectively. No matter how low they go, however, the GLP-1 leaders can still be undercut by compounders, Steven Grossman, policy and regulatory consultant and author of the FDA Matters blog, told BioSpace this week.   Speaking of Lilly, the Indianapolis-based pharma had a busy week, reporting 20% weight loss in a mid-stage study of its amylin agonist eloralintide that William Blair analysts said “validates [the] amylin agonist class.” Lilly also netted two new partners, inking a $1.2 billion RNAi pact with SangeneBio to target metabolic diseases and licensing a genetic eye disease therapy from MeiraGTx Holdings for up to $475 million.   On the regulatory front, the FDA awarded the second round of priority review vouchers under its new Commissioner's National Priority Vouchers program. Unlike the first cohort of vouchers, which was announced in October, this group mostly consisted of products already on the market—with the exception of Lilly's orforglipron.   Finally, BioSpace dives into one the hottest trends in the immunology and inflammation (I&I) space—pipeline-in-a-product. Possibly motivated by blockbuster drugs like AbbVie's Skyrizi and Rinvoq and Regeneron and Sanofi's Dupixent, companies are optimizing shots on multiple goals in this lucrative space.  

After taking some much-needed time off before, during, and after our family cruise, I'm finally back behind the mic — and whew, it's been a minute! In this episode, I'm catching you up on life, how hard it can be to get back into your rhythm, and the lessons I learned along the way.This isn't just a vacation recap. It's a reminder that life is happening right now. You can't wait until you lose the weight or have it all together to make memories. From cruise chaos to core memories, I'm sharing how “someday” never comes, why you should take the trip, and what going with the flow taught me about self-acceptance and joy.Plus, I'll share a few of my favorite Amazon outfit finds and cruise must haves that made the trip easier, cuter, and a little more glam (even in mom mode).

Welcome back to The Weight Loss Collab! In today's episode, bariatric surgeon and obesity medicine expert Dr. Dovec is diving deep into the world of GLP-1 medications—those popular injectables like Ozempic, Wegovy, Zepbound, and Mounjaro that everyone's been talking about. Whether you're fresh out of bariatric surgery, struggling with weight plateaus, have a lower or higher BMI, or you're just curious if these meds might be right for you, Dr. Dovec breaks down exactly how GLP-1s work, who benefits most, potential side effects, and how to personalize your treatment for the best results. Plus, she compared options like phentermine and Contrave, and gives real talk about surgery versus medication. If you're looking for up-to-date, honest guidance on weight loss medications and a supportive community cheering you on, this episode is packed with insights and actionable advice!

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. If you've had bariatric surgery, you already know what it means to commit fully to your health.  But even with your best efforts, bodies adapt, hormones shift, and life adds its own complications. When weight begins to creep back, many people turn to GLP-1 medications for support, and that raises a crucial question: How well do GLP-1s actually work after bariatric surgery?I recently heard from a listener living this exact experience — someone who lost more than 200 pounds after gastric bypass and has now started Zepbound to address weight regain. Her story opens the door to an important conversation about why GLP-1 medications can behave differently in a post-bariatric body, why results may not mirror those of someone without surgical history, and how to redefine success when you've already achieved a significant transformation.ReferencesThe Obesity Guide: Behind the Curtain (Season 1)The Obesity Guide: Behind the Curtain (Season 2) - Includes access to the December 21-Day Challenge with daily coaching, actionable steps, and community support to end your year with momentum.Audio Stamps00:40 - Dr. Rentea shares a heartwarming reunion at the VA, reconnecting with former colleagues and reflecting on how far she's come in her weight loss journey.07:10 - Fan mail question: Does Zepbound (tirzepatide) work the same after gastric bypass surgery, and what weight loss results should you expect?09:11 - Why post-bariatric patients often respond better to GLP-1 medications and become "hyper responders" at lower doses.16:18 - Redefining success: why focusing on your relationship with food and sustainability matters more than hitting a specific weight loss percentage.17:48 - Common post-surgery pitfalls including grazing patterns, excessive step counting, and neglecting body composition tracking.20:42 - Information on the December 21-Day Challenge and upcoming 30/30 program rounds.All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com ✨ Season 2 of Behind the Curtain is officially live! ✨ You can join the season on its own or take it a step further by opting into the live 21-Day Challenge with Dr. Rentea, running December 1–21—the perfect way to finish the year strong and head into the holidays with momentum.

In this powerful episode, I will break down one of the biggest developments in obesity and diabetes treatment in U.S. history. Two major pharmaceutical companies - Eli Lilly and Novo Nordisk - have reached a groundbreaking agreement with the administration that will drastically reduce the prices of popular medications like Wegovy, Ozempic, and Zepbound. This pricing model could transform how obesity medications are covered, distributed, and accessed across Medicare, Medicaid, and direct-to-consumer platforms. Tune in to learn what this new deal means for patients, healthcare providers, and public health overall—and why it's being called a game changer for people struggling with obesity and related health conditions. Episode Highlights: Major price cuts announced for Wegovy, Ozempic, and Zepbound under a new federal deal   Medicare to cover obesity drugs for the first time through a five-year pilot program   Medicaid given the option to join discounted pricing starting 2026   Team Rx launches a direct-to-consumer model cutting out costly middlemen   Lower cash prices for GLP-1 medications and upcoming oral versions   Eli Lilly and Novo Nordisk to invest billions in U.S. manufacturing   Program expected to improve access, affordability, and supply of obesity and diabetes meds   Ongoing push for the Treat and Reduce Obesity Act to expand national coverage   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

You've heard of Ozempic Face.  And Ozempic Vulva.  Now there's Ozempic Breast!  That's the loss of breast volume and sagging of the breast after the use of GLP-1 drugs like Ozempic and Zepbound.  On this show, we discuss how breast lifting after weight loss or after pregnancy can restore a beautiful shape to the breast....without the use of implants.  And we discussed the recent FDA warnings to 18 websites selling botulinum toxins on the web to unsuspecting people.  Tune in!

In Part 1 we looked at an early study of GLP1 drugs and muscle loss. Today we'll look at two more recent studies, one for Eli Lilly's drug tirzepatide and one for Novo Nordisk's drug semaglutide. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Andrew Walworth, Tom Bevan and Carl Cannon discuss new polling on candidate preferences for the 2028 presidential nomination for both parties, and this morning's reporting from Politico that Secretary of State Marco Rubio is telling close associates that he believes Vice President JD Vance is the frontrunner for the Republican nomination. Then, they talk about the role of energy prices in last Tuesday's election, and President Donald Trump's new agreement with pharmaceutical manufacturers to sell GLP-1 products like Wegovy and Zepbound at discounted prices to Medicare and Medicaid recipients. Then finally, the guys discuss the jury verdict in Washington, DC of the former Justice Department employee who threw a sandwich at a federal officer in protest last August. Plus, this week's “You Cannot Be Serious” stories. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today on America in the MorningShutdown Flight Delays On a day when the Senate is hoping to vote later today on ending the government shutdown, today is the day that the FAA has ordered flights to be cut due to staffing shortages.  Yesterday, there were 200 canceled flights across the nation – today that number is expected to be above one thousand, with thousands more delayed.  Correspondent Ed Donahue reports that air traffic controllers and TSA agents received a zero paycheck for the second time since the government shutdown began, and Transportation Secretary Sean Duffy, speaking on Fox News, says the flight cutback is all about air safety.   Pelosi's Retirement After nearly 40 years on Capitol Hill, Nancy Pelosi is retiring from Congress.  Correspondent Clayton Neville reports.   Musk's Big Payday The world may soon have its first “Trillionaire.”  Joan Jones has the story of Elon Musk's payday approval granted by Tesla shareholders.   NFL Player's Suicide There is shock through the sports world after 24-year-old Dallas Cowboys defensive end Marshawn Kneeland took his own life after being involved in a police chase.  The story from correspondent Gethin Coolbaugh.   Senate Blocks Venezuela Measure The Senate has blocked a measure to limit military action by the Trump administration against Venezuela.   Hoagie Hurler Cleared Justice is served for a man who hurled a hoagie at a federal immigration agent in Washington.  The details from correspondent Jennifer King.     Latest On SNAP & Government Shutdown Senators appear closer to ending the government shutdown, now in its 38th day, as a vote is expected later today on a deal that could re-open the government, but it's far from certain enough Democrats are on board.  John Stolnis has more from Washington.   Virginia Teacher's Day In Court A jury awarded $10 million dollars in a civil case to a Virginia teacher who was shot by a first grade student in 2023.  As correspondent Haya Panjwani reports Abagail Zwerner still has a bullet inside her chest from that shooting, and her legal team, speaking outside the courthouse, says her long ordeal is far from over – audio courtesy of Court TV.   Heritage Foundation Fallout The fallout continues surrounding the conservative think tank The Heritage Foundation following an interview by Tucker Carlson with Nick Fuentes.  Correspondent Clayton Neville reports.   SCOTUS On Passports The Supreme Court on Thursday allowed the Trump administration to require the sex designation on US passports to align with a traveler's biological sex, a blow to transgender and non-binary Americans who have argued the policy is unconstitutional.   Trump's Drug Deal At the White House, President Trump unveiled a new deal to expand coverage and lower costs on obesity drugs including Wegovy and Zepbound.  Lisa Dwyer reports.    New Member Of Abraham Accords The White House announced that Kazakhstan will agree to normalizing relations with Israel and join the Abraham Accords, joining the United Arab Emirates, Bahrain, and Morocco who formalized relations with Israel during President Trump's first term in office. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mazel morons! Today Ben's feeling skinny (thank you, Zepbound), Josh's dishing gym wisdom, and together we unpack Ozempic science, LA beauty standards, overpriced popcorn, dopamine traps, why you should never pickle on vacation, and why LA makes everyone just a little hotter. We also confess our screen-time addictions, talk dad life, and end with a What Are Ya Nuts that involves Target, 20 grand in cash, and questionable decision-making. Love ya! Leave us a voicemail here!Follow us on Instagram and TikTok! Sponsors:Caraway - Plus, if you visit Carawayhome.com/GOOD10 you can take an additional 10% off your next purchase.goodwipes - Just buy a pack at Target, Walmart, Kroger—or your local store—then head to goodwipes.com/GOODGUYS, text them your receipt and get reimbursed!Skims - Shop SKIMS Mens at SKIMS.comQuo - Quo is offering my listeners 20% off your first 6 months at Quo.com/goodguysOlipop - Get $2 off a 4-pack of OLIPOP- Works on any flavor of 4-pack, including Spongebob, any retailer at drinkolipop.com/GOODGUYSHome Chef - For a limited time, Home Chef is offering my listeners FIFTY PERCENT OFF and free shipping for your first box PLUS free dessert for life! Go to HomeChef.com/GOODGUYSPlease note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the latest episode of The Mom Wars, Bethany talks us through her weight-loss journey with Zepbound, and the girls discuss the latest postpartum body discourse.

Trump unveils deal to expand coverage and lower costs on obesity drugs Wegovy and Zepbound. AP's Lisa Dwyer reports.

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices

Exclusive OTP Savings HTTPS://www.otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We've all heard the headlines about GLP-1s. The miracle weight-loss meds. The quick fix. The controversy.But what does it actually feel like to live it?Nicole has been my client for 18 months and a year ago she started Zepbound  and has lost nearly 60 pounds. But that's not the only story.The story is about what happened underneath the weight loss—the food noise that finally quieted, the skill work that still had to happen even with the meds, and the life she's living now that no diet ever gave her.What we talk about:What “food noise” really feels like — and what happens when it finally goes quietThe difference between biological change and behavioral changeWhy the meds don't replace the work — they create space for itThe “finish your plate” brain that doesn't disappear overnightHow Nicole's body image is evolving while she's still losing weightConnect with JordanaFind me on InstagramSign up for my Monday newsletter with lots of nutrition, body image and mindset tipsSchedule a free discovery call to talk more about working together Listen to more episodes of The Diet Diaries

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's focus is on a series of significant advancements that are poised to reshape the landscape of drug development, regulatory standards, and patient care.Eli Lilly has made remarkable strides with its dual-action obesity medications, Zepbound and Mounjaro. Despite being removed from the CVS formulary, these drugs have achieved exceptional sales figures, reaching $10 billion in a single quarter. This success can be attributed to Lilly's innovative direct-to-consumer sales strategy, which exemplifies how modern marketing approaches can overcome traditional market barriers. Additionally, Eli Lilly's partnership with Walmart to expand access to Zepbound through retail pharmacy pickups exemplifies a strategic approach to enhancing patient access to crucial medications. By leveraging Walmart's extensive retail network, this collaboration facilitates easier access to obesity treatments—a significant public health challenge—enhancing both patient convenience and broadening market reach for Lilly's products. These achievements not only highlight the potential of strategic marketing but also underscore a growing demand for effective obesity treatments within the pharmaceutical industry.In another exciting development, Alnylam Pharmaceuticals has reported impressive sales figures for Amvuttra, a treatment for transthyretin amyloid cardiomyopathy. Surpassing analysts' expectations, this success signals a growing market for treatments targeting rare diseases and emphasizes the importance of strategic market expansion to reach underserved patient populations.Meanwhile, Bristol Myers Squibb's anticipated schizophrenia treatment, Cobenfy, has experienced a lukewarm market entry. While meeting initial expectations in its first year, it has yet to create the breakthrough impact investors anticipated. This situation highlights the challenges even well-hyped pharmaceuticals face upon launch and underscores the need for continuous strategic planning to ensure market penetration and sustained growth.A surprising development in mergers and acquisitions comes from Novo Nordisk's $6.5 billion counteroffer to acquire Metsera, an obesity biotech initially targeted by Pfizer. This aggressive move reflects intense competition in the obesity drug market and illustrates the high stakes involved in acquiring promising biotech assets that could potentially transform treatment paradigms for chronic conditions like obesity.The vaccine industry is navigating its own set of challenges with declining sales across the board. However, Merck's adult pneumococcal vaccine Capvaxive has shown promising initial sales figures. As the first pneumococcal vaccine specifically designed for adults, Capvaxive indicates a potential niche market that Merck could successfully capture.On the regulatory front, significant measures are being taken by the FDA to boost biosimilar availability against drug pricing pressures. New draft guidance aims to eliminate clinical testing requirements for biosimilars and categorize all approved biosimilars as "interchangeable." This initiative could significantly reduce biologic medicine costs post-patent expiration and increase competition in the market, potentially making essential medications more accessible to patients. Additionally, the FDA is proposing streamlined biosimilar approval pathways aimed at reducing overall bio-drug costs—a welcome move reflecting concerted efforts to make essential medications more affordable and accessible globally.Argenx has reported positive trial results for Vyvgart in treating generalized myasthenia gravis (gMG), highlighting its commitment to addressing unmet needs within this patient population. These findings could expand treatment options for gMG patients who have been previously overlooked in thSupport the show

A gain in same-store sales wasn't enough to reel investors back into Starbucks (SBUX). Diane King Hall says a lack of outlook had many investors scratching their heads. Eli Lilly (LLY) rallied after showing strength in its Mounjaro and Zepbound weight-loss drugs. Estée Lauder (EL) posted a profit that Diane King Hall calls a "sigh of relief" for investors.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

This Day in Legal History: October ManifestoOn October 30, 1905, Tsar Nicholas II of Russia issued the October Manifesto in response to mounting unrest and revolutionary fervor sweeping the Russian Empire. The 1905 Revolution had erupted earlier that year following the Bloody Sunday massacre, in which unarmed protesters were gunned down by imperial guards. Strikes, peasant revolts, and mutinies within the military and navy intensified public pressure for reform. The October Manifesto promised several liberalizing measures: the creation of a legislative Duma (parliament), expansion of civil liberties including freedom of speech, assembly, and conscience, and a commitment that no law would be enacted without the Duma's consent.Though revolutionary factions remained skeptical, the manifesto temporarily quelled widespread unrest and led to the formation of Russia's first constitutional structure. It marked the first time autocratic power in Russia was publicly limited by law, at least in theory. However, the tsarist regime maintained significant control: Nicholas retained the right to dissolve the Duma at will and manipulate election laws. Conservative forces viewed the manifesto as a concession made under duress, while radicals criticized it as too limited and unenforceable.The October Manifesto also split opposition forces. Some liberals, known as Octobrists, supported working within the new constitutional framework. Others, including the Bolsheviks and Socialist Revolutionaries, dismissed the document as a façade and continued to push for broader revolution. In legal terms, the manifesto introduced the concept of legislative consent into Russian governance, establishing a precedent for popular representation in lawmaking. Although the Duma's actual power remained constrained, the October Manifesto set the stage for future political conflicts that would culminate in the Russian Revolutions of 1917.The Trump administration's recent approvals for oil and gas leasing in Alaska and road development projects are drawing scrutiny from environmental groups, who say the decisions were made opaquely during a government shutdown, limiting their ability to challenge them in court. These projects include reopening leasing in the Arctic National Wildlife Refuge (ANWR), issuing permits for the 211-mile Ambler Road to mining sites, and approving a controversial land exchange to allow road construction through the Izembek National Wildlife Refuge wilderness. Environmental attorneys argue that key documents and analyses justifying these decisions remain unavailable, complicating legal strategies.The Interior Department, operating with a reduced staff, has only offered links to decision documents, providing little insight into environmental protections or regulatory compliance. Although these projects have been previously contested in court, the lack of transparency surrounding the latest approvals hinders further action. Some legal experts suggest potential conflicts of interest—such as the U.S. acquiring a stake in a company tied to the Ambler Road—could be grounds for future lawsuits. Additionally, the Izembek land swap may face legal challenges for bypassing required congressional approval.Environmental Groups Challenged in Fighting Trump's Alaska MovesThree former Morgan Stanley financial advisers are suing the U.S. Department of Labor over a recent advisory opinion that they argue unlawfully shields the bank from arbitration claims related to unpaid deferred compensation. Filed in Manhattan federal court, the lawsuit alleges that the Labor Department's September 9 finding—that Morgan Stanley's deferred compensation plan does not qualify as an employee benefit pension plan under ERISA—conflicts with two prior court rulings that said it does.The plaintiffs, Steve Sheresky, Jeffrey Samsen, and Nicholas Sutro, say the opinion was “arbitrary and capricious” and would undermine their efforts, and those of other former employees, to arbitrate claims over canceled or unpaid compensation. They also claim Morgan Stanley is already using the Labor Department's stance to dismiss ongoing claims and seek reimbursement of legal costs.Though Morgan Stanley is not a defendant in the suit, the plaintiffs argue the agency overstepped its authority and are asking the court to revoke the advisory opinion under the Administrative Procedure Act. The case, Sheresky et al v. U.S. Department of Labor, raises broader questions about administrative agencies issuing legal interpretations that can influence private litigation outcomes without proper judicial or legislative review.Former Morgan Stanley advisers sue US Labor Department | ReutersEli Lilly has announced a new partnership with Walmart to offer its weight-loss drug Zepbound at discounted, direct-to-consumer prices through Walmart pharmacies nationwide. This marks the first time customers using the LillyDirect platform can pick up the medication in person at a retail location. The lowest dose of Zepbound will be available for $349 per month for self-paying patients.The move is part of Lilly's broader strategy to expand access and boost market share in the competitive obesity drug space, currently valued at around $150 billion. Zepbound competes directly with Novo Nordisk's Wegovy, but recent data suggests Lilly has pulled ahead in prescriptions, despite Novo's earlier market entry.Lilly reported that around 35% of Zepbound prescriptions in Q2 came from cash-paying customers using LillyDirect. Both Lilly and Novo have also made their weight-loss drugs available through various telehealth platforms, further expanding patient access.Lilly, Walmart launch first retail pick-up option for weight-loss drug | ReutersA piece I wrote for Forbes earlier this week looks at the escalating tensions surrounding digital services taxes (DSTs), with France once again moving to raise its DST—from 3% to 15%—primarily targeting U.S. tech giants like Google, Meta, and Amazon. The U.S. has responded with familiar threats of tariffs and trade retaliation, repeating a now well-worn pattern of diplomatic pushback without addressing the underlying issue. That issue is structural: the global tax framework was built around physical presence, but today's digital economy allows companies to generate profits in countries where they have no offices, employees, or infrastructure.As frustration builds in countries watching tech firms reap profits without corresponding local tax contributions, DSTs have become a tool to reclaim taxing rights. In response, nearly 140 countries have worked through the OECD to build a two-pillar international solution. Pillar One aims to reallocate taxing rights based on where users are located; Pillar Two introduces a global minimum tax. Yet, while other countries move forward, the U.S. continues to resist fully embracing Pillar One—out of concern for political optics and revenue loss.That resistance is counterproductive. By refusing to commit to a multilateral framework, the U.S. is guaranteeing the very outcome it opposes: a fragmented global tax landscape where each country sets its own rules. The current whac-a-mole strategy—reacting to every unilateral move with threats—offers no long-term protection for U.S. companies and only heightens global instability. It's time for the U.S. to stop playing defense and help finalize a framework that reflects the realities of the digital economy.Whac-A-Mole Taxation Battles Will Persist Without A Global Deal This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Welcome to Ozempic Weightloss Unlocked, the podcast dedicated to exploring every facet of Ozempic—from its medical roots to its reputation as a game-changing weight loss trend.Ozempic was originally developed for those managing type 2 diabetes. Its active ingredient is called semaglutide, which mimics a natural hormone in the body known as glucagon-like peptide one. This hormone helps regulate blood sugar and reduces appetite, making you feel fuller for longer. According to Noom, this mechanism led many people to lose weight while taking Ozempic, turning it into a household name far beyond the diabetes community.The medication is injected once weekly. In clinical studies, people taking Ozempic at the highest dose often lost an average of about 15 pounds, which was roughly seven percent of their body weight over forty weeks. Wegovy, a similar medication containing the same active ingredient, is FDA-approved specifically for weight loss and is generally prescribed at a higher dose than Ozempic, leading to even greater results with weight loss reductions closer to fifteen percent of starting body weight.As for how quickly you might lose weight, listeners can expect to see small changes in the first month, with greater progress over several months as the dosage increases. Weight loss is highly dependent on personal factors like diet, exercise, hormones, and health history. GoodRx notes that women may actually be “hyper-responders” to semaglutide, but those with lower estrogen levels, such as postmenopausal women not undergoing hormone therapy, may lose less weight. The key point is that no medication works the same for everyone.Equally important is that Ozempic is not FDA-approved specifically for weight loss—Wegovy and Zepbound are the medications formally approved for this use. People who do not see weight loss benefits on Ozempic may benefit from switching to these alternatives. Ozempic does, however, offer additional health benefits, including improved blood sugar control and reduced risk for heart and kidney disease.Recent news from University College London and the Pharmaceutical Journal has brought new attention to semaglutide's heart health effects. In a large international trial, semaglutide was shown to cut the risk of heart attacks and other cardiac events by about twenty percent, regardless of how much weight was lost. Researchers found that shrinking waistlines accounted for only about a third of the heart benefit, suggesting the drug protects heart health in other ways, including supporting blood vessel health and lowering inflammation. This discovery could profoundly change how Ozempic and similar medications are prescribed—not just for obesity, but possibly for cardiovascular protection even among those with smaller body mass indexes.Another headline update: Ozempic may soon be available as a pill. Rutgers reports that a tablet form of GLP-1 therapy is closer than most people realize, though the current pills don't match the weight loss impact of injectable semaglutide just yet.Ozempic comes with possible side effects, ranging from gastrointestinal issues like nausea to risk of more serious complications, especially at higher doses. Pricing remains high, often around one thousand dollars per month, with insurance rarely covering it for off-label weight loss.So, what can listeners do to boost their chances of success on Ozempic? Noom and GoodRx recommend focusing on balanced meals high in lean proteins, fiber, healthy fats, and hydration. Minimally processed foods and regular exercise can help maximize results and minimize side effects. Collaborate closely with your healthcare professional to tailor your approach based on your unique health profile and goals. If you experience limited benefit, do not hesitate to ask your provider about alternate GLP-1 therapies or other options.Before wrapping up, let's review today's key updates. Ozempic is becoming both more accessible and controversial as demand grows for weight loss, age reversal, and heart health. Major clinical studies are changing the conversation around who benefits most from these medications and how they might be used in the future. The science is evolving fast—today, Ozempic is known for weight loss, but tomorrow it may be just as well-known for protecting hearts and possibly even slowing ageing.Thank you for tuning in to Ozempic Weightloss Unlocked. Subscribe to stay updated week by week as we track new research, news, and real stories about Ozempic and the evolving landscape of GLP-1 therapies. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

The gut is in the news. It's really in the news. Catapulted there from exciting developments coming from laboratories all around the world. Links of gut health with overall health are now quite clear and surprising connections are being discovered between gut health and things like dementia and Alzheimer's. But how does the gut communicate with other parts of the body in ways that make it this important, and where does the brain figure into all this? Well, there's some interesting science going on in this topic, and a leading person in this area is Dr. Diego Bohorquez. Dr. Bohorquez is the associate professor of medicine, of molecular genetics and microbiology and of cell biology at the Duke University School of Medicine. Interview Transcript Diego, your bio shows that you blend work in nutritional biochemistry, gastrointestinal physiology, and sensory neurobiology. It took me a little time to figure out just what these things are, but what this represents, to be a little more serious, is a unique ability to understand that the different parts of the body, the gut and the brain in particular, interact a lot. And you're in a very good position to understand how that happens. Let's dive in with the kind of a basic question. What got you interested in this interaction of the gut with the brain and why care about it? Yes. Kelly, I think that that's all technicalese for saying that we are at the interface of food, the gut, and the brain. Apart from the fact that we are what we eat and if we truly believe that then food will be shaping us. Not only our body, but also like our belief systems, our societal systems, and so on and so forth. I don't think that that is anything new. However, what is new is the ability of the gut to guide our decision making. And it was interesting to hear in your introduction that now the gut is all in the news. In 2005 when I came to the United States, and I was at North Carolina State University, and I joined a graduate school. I remember taking a graduate course in physiology in 2007. And when the professor opened the session on gastrointestinal physiology, he said the gut is one of the most misunderstood and mysterious organs. It has almost as many neurons as the spinal cord, or more. But honestly, we don't give a lot of respect to the gut. We only think that it does some digestion and absorption, and we judge it more for the value of its products of digestion than what it does for the entire body. And fast forward almost 20 years later now, partly my laboratory and other laboratories that have entered this field since some of our discoveries started to emerge, it's very clearly showing that the gut not only has its own sensory system that is behind what we call gut feelings. The gut feelings are actually real. But it actually can influence our decision making. Like specifically, we have shown that our ability to choose sugars and consume sugars and feel sugars and choose them over sweeteners, it can be pinpointed to a specific set of cells in the intestine called neuropod cells and specific receptors in those cells. And the intestine is right after the stomach. And this is where these cells are exposed to the surface of the gut and detect the chemical composition of food to guide our decision making. Let's talk about that a little bit more. So, you've got this axis, or this means of communication between the gut and the brain going on. And let's talk about how it affects what we eat. You just alluded to the fact that it's pretty important. What does it tell us? What to eat, how much to eat? What we like to eat? When we're hungry, when we've had enough? How does this affect our eating? We are beginning to understand how much it affects this eating. And obviously we are departing from understanding, right? And an understanding is cognitive. In the 1500s is when the idea of 'we think therefore we are,' came online. And we needed to think things before we actually will understand them. But well before thinking them, we actually feel them. And you probably have noticed that. If anybody offers you maybe a cup of water at 5:00 AM, 6:00 AM, it will be very welcome. Especially with it's a little bit warm. If they offer you a steak at 5:00 AM you will run away from that. But in fact, you'll create distress I think unless you are like severely jet lagged. And a lot of those feelings not only come from the experience, but even if you blind are blindfolded, your gut will be able to evaluate what you just ingested. And it is because the intestine, it is the point where those molecules in the meal or in the drink, will be either absorbed to become part of who we are, or will be excreting and expelled. And that absorption of who we are is dependent on the context. Like for instance, the part of the month, morning versus afternoon, health status, age, will influence specifically like at the molecular level, what it is that we need to continue to thrive. It sounds like there's lots of potential for the gut and its interaction with the brain working in concert with the rest of the body. Things are in balance and working like they should be. But there are lots of things going on out there that disrupt that. Tell us more about that and how it affects eating. For example, the levels of obesity have risen so much in the past decades. How does the gut figure into that, for example. Could there be environmental things like the microplastics or exposure to toxins like pesticides and things that might be affecting the gut that throws the system off? I think that that is a very timely question for the days. Over the last 10 years, we have documented that the gut has its own sensory system. And in fact, it's one of the most ancient sensory systems. At the very beginning, 600 million years ago, when cells started to coalesce into animals, multicellular organisms, they needed to eat. And they needed to not only find the food but create a sensory representation of the food. What do I mean by that? Eating algae is very different than eating bacteria, for instance. And the gut needed to have these sensors to be able to rapidly create first a representation, this is bacteria. And then put out the molecules to digest that bacterium or those bacteria. And then ultimately absorb them, turn them into metabolites and continue to thrive, right? Perhaps reproduce, coalesce and so on and so forth. This is a very important concept because our reality, the reality that you and I are having right now, it is guided by our senses. And we have multiple senses. Like for instance, we are able to communicate partly because of the sound that is going through our ears. And then there are inner hair cells that are picking up those waves. Passing that information to the brain, decoding it, and then the brain coalesces with everything else and saying like, 'okay, Diego, you're in a podcast. Make sure that you say something hopefully reasonable, right?' What the gut is doing, as a true sensory system, is also detecting the food that we have ingested, creating a rapid representation. It's not the reality itself. It is a representation of the reality. Because when we eat an apple, ultimately the gut, what it's doing is creating a representation that was an apple and not an orange. And then telling the brain, look, you're going to get some glucose, some fiber, a little bit of a skin. And you may need to adjust it with water, right? And then that will trigger the desire to, 'oh, maybe I should have also a cup of water.' Why does that have to do with, the societal issues that we are facing? Since the 1970s, we learned to disentangle the sensory experience of food, not only as humans or scientists, but also that was extrapolated to the society. So, if you go and look, and it is not a secret, it has been very well documented. For instance, the ability to put artificial sweeteners out there. It has really changed the health landscape. And it was just a normal progression of how it is that we humans think. We thought well, people consume sugars because they're sweet. If we take out the calorie and we just leave the sweetness, it will be totally fine because it's benign. You're not consuming anything else. However, the gut, you have promised the gut something sweet. That it has always, or almost always, invariably, been associated with a nutritional value. Then the gut is fed this information that is skewed. Then it has to go and adjust. And we actually have demonstrated that in the laboratory that when the neuro pods detect a non-caloric sweetener, they actually release a different neurotransmitter that communicates to the brain that artificial sweeteners have arrived at the gut, as opposed to glucose, which triggers the release of glutamate. And that glutamate is essential for the organism to know that we have consumed sugar. Is it safe to say then that the body has evolved to be able to have effective signaling and feedback systems with things that are found out there in nature, like sugar or an apple or an orange. But when you start introducing things that don't exist in nature, like the artificial sweeteners, then bad things can happen. Yes. Because imagine right now your brain will swap the reality and you will transport yourself or the beach. You may not even have the clothing ready to confront the breeze of the beach, right? Or the salt. You would have not been prepared, right? We evolved around nature because nature was there before us. Therefore, we had gradually adjusted to what nature had to offer. Eventually we introduced fire, and we were able to transform simple or complex carbohydrates into something digestible. And then the body had the ability to adjust to it. And not only the body, but also the microbiota in the gut. Now we are talking about like the transformation of foods. And especially I think in the last 30 years we have been able to transform those foods. Beverages have sweeteners now. We have energy drinks that have a composition of vitamins and other things. And while those things individually perhaps are not innocuous, we haven't explored what is the conglomerate effect on long-term health. When we talk about these things being added to foods, I mean, there are whole classes of things like colorings and dyes and artificial sweeteners and things. And then there are processing things that go on, like extrusion and different things that take something like wheat or corn and turn it into something that the body is not accustomed to dealing with. Is the body incapable of perceiving what these things are? Does it get send out wrong signals? Why should we be worried about these things? I don't think that we should be worried necessarily because that's alarming, right? But we should be aware, certainly, that the body keeps tabs on it. Something very simple. If you rub water on your skin versus if you rub oil on your skin, your brain already starts to perceive that substance as different. Now, imagine the gut is going to know exactly the same thing. It knows what water is. It knows what oil is. It knows what carbs are. It knows what protein is. And depending on what it has been fed for, thousands of years, it will be able to create that representation as I alluded to. And therefore, if there is a foreign composition, it's going to have to adjust to the situation. And that is how you can end up altering the composition of a regular body. Because like, for instance, in nature if you go and look at native populations that live very close to nature, you know, the body composition is in a certain form. But in cities where you're exposed to foods that have been transformed, the body composition is very different. And I'm not talking only about body weight, but also height, shape, you know. That certainly makes sense. You know, something that's been in the news a lot lately are the GLP1 drugs like Ozempic and Zepbound and they have very powerful effects on appetite, satiety, and weight regulation. How is the gut brain axis involved in this? I would like to make a couple of points in there.The first one is that glucagon-like peptide is obviously is very similar to glucagon. Glucagon is produced in the pancreas. Glucagon-like peptide is actually produced in the gut. And it is produced by these neuro pod cells that also produce some neurotransmitters. And it is produced in response to specific nutrients like glucose. And it is a signal glucagon like peptide 1. It is a signal for not only adjusting insulin release, but it is also a signal for coordinating what has arrived in the gut. It does affect motility. Eventually it is thought that goes into the bloodstream and affects the nervous system. However, and I said it is thought because the brain also produces glucagon-like peptide. There are cells in the skin. There are cells in the urethra. There are cells in the bladder. There are cell cells in the spinal cord in the choroid plexus that is exposed to the cerebral spinal fluid that also produces some of these peptides as signaling molecules. And I have to make that clarification because traditionally it has been thought to be a signal from the gut, per se. But these are just signaling molecules. The second part is that the arrival of Ozempic, I thought that it was obviously a very important step not only scientifically, but also societally. Why? Because up until 1980s and I have thought with many colleagues especially in medicine. And they will say like, when an obese patient will arrive in the office, first of all, there was not a lot of options. One of the recommendations is - are you doing enough dieting or exercise? And if the patient was like, you know, I'm not eating even a lot, but I'm gaining weight. Or it was perhaps psychosomatic because we didn't have the molecular language to be able to explain what was going on. I think that Ozempic clearly has shown that when we are affecting a set of receptors in the body, perhaps in the gut, it's changing many different things. Not only like food intake, but also alcohol intake and how people feel. I think that is definitely a breakthrough. Where are we going from here? I think that this is the beginning of a long conversation in which we are going to be looking for options not only to reduce the amount of food, but actually to steer food choices from the gut. Because the gut is still as an external surface. And that's what I've mentioned that the discovery that these neuro pot cells can guide our food choices, I think that is very attractive for future options on how we are going to steer decision making. So, let me ask a final question. You partly just answered it, but where do you see this field going? What are you excited about and what do you think the next frontiers will be? I think that I'm a little bit more close to nature. I think that on moving forward, there's all obviously a lot of technologies and molecules that are going to be developed to perhaps treat some disorders. Not only related to the body, but also to the mind. Chronic depression and so on and so forth. But I think a lot of these elements have already been explored in nature. And if we look back anthropologically, people were solving the issue of medicine with their environment. In fact, what we call metropolitan medicine evolved largely from natural medicine. And in fact, today, 80% of the world, they still rely directly on plants and other compounds that are directly from plants for healthcare. I think that there is a lot to learn in there and a lot to merge, especially with the new technologies on diagnostics. And I think that that's a very exciting area to keep nature in mind. And when I said nature is like our relationship with environment, right? Bio Diego V. Bohorquez is an associate professor of medicine, associate professor in molecular genetics and microbiology, associate professor of cell biology, associate research professor in neurobiology, and an associate professor in pathology at Duke University's Department of Medicine. Bohorquez is a gut-brain neuroscientist and holds a Ph.D. from North Carolina State University. His research focus is to unveil how the brain perceives what the gut feels, how food in the intestine is sensed by our body, and how a sensory signal from a nutrient is transformed into an electrical signal that alters behavior.

Send us a textDr. Acosta returns to Causes or Cures to talk about the next big leap in obesity research: using genetics and machine learning to predict which patients will get side effects to popular GLP-1 weight-loss medications like Wegovy and Zepbound. Previously, he was on Causes or Cures to discuss your individual obesity type. He and his team are uncovering why some people experience major weight loss while others face tough side effects—especially nausea. The goal? True precision medicine for obesity: matching the right treatment to the right person before treatment even begins. (You can learn more about their available tests and company here.) Topics We DiscussDr. Acosta's background and what drew him to obesity researchWhy not all obesity is the same—and why that matters for patients and doctorsThe most common questions patients ask about GLP-1 drugs like Wegovy and ZepboundHow big a problem side effects like nausea really are in practiceNew research using genetic markers to predict who's more likely to experience side effectsWhether eating style affects nausea and how Dr. Acosta coaches patients on nutrition while using these medicationsThe possibility of genetic testing before prescribing GLP-1sWhat we know about rarer side effects, from vision to hearing changes, if he thinks more side effects will emergeWhat “satiation” (feeling full) means and why it varies so much between peopleHow genetic risk and satiation scores could determine which obesity treatment works bestDr. Acosta's thoughts on obesity prevention, especially on renewed energy to take on the unhealthy food industryThe persistence of stigma—why “willpower” doesn't tell the whole storyWhether the current obsession with obesity drugs distracts from prevention, nutrition, and community health Listen if you've ever wondered:Why GLP-1 drugs don't work the same for everyoneWhat your genes have to do with weight loss, feeling full and side effectsHow soon doctors could use genetic tests to personalize obesity treatmentWhether prevention is being overshadowed by the pharma spotlightWhy it mattersObesity isn't a one-size-fits-all condition—and neither should its treatment be. Dr. Acosta's research could mark a turning point in how we approach weight loss: scientifically, compassionately, and individually. Dr. Acosta is a Consultant of Gastroenterology and Hepatology at the Mayo Clinic, as well as an Associate Professor of Medicine. His research focus is on gastrointestinal physiology and the complexity of food intake regulation as it relates to obesity. You can learn more about his work here.You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her WEEKLY newsletter here! (Now featuring interviews with top experts on health you care about!)Support the show

According to a KFF poll, about one in eight, or 12%, of adults in the United States have used a GLP-1 medicine like Ozempic, Trulicity, Victoza, Mounjaro, Wegovy, or Zepbound. These drugs were originally developed to treat diabetes, but quickly started being prescribed for weight loss and other uses. While they seem like wonder drugs, GLP-1 medicines do cause side effects and have risks. Nausea, vomiting, diarrhea, and constipation are common side effects. The drugs also can cause dizziness, headaches, and elevated heartbeat.  Dr. Neil Iyengar is a breast medical oncologist who studies how diet and exercise can improve quality of life for people with breast cancer. He's also prescribed GLP-1 medicines for the people he cares for. Listen to the episode to hear Dr. Iyengar explain: how GLP-1 medicines work the risks these drugs may pose for people receiving chemotherapy, immunotherapy, or a CDK4/6 inhibitor why he works closely with a weight loss specialist or endocrinologist when prescribing these medicines why the medicines work best when a person also makes lifestyle changes

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever notice how travel can completely throw off your routine—especially when you're on a weight loss plan? Between airports, restaurants, and unpredictable schedules, it can feel like all your progress is at risk the moment you pack your bags.In this episode, we're tackling one of the biggest challenges my patients—and honestly, I—face when it comes to staying consistent: travel. Whether your trip is for work, vacation, or a bit of both, this one's for you.We'll cover:Smart eating while travelingPlanning for balanced meals on the goStaying active during your tripTraveling smoothly with your medicationsWhy you shouldn't change your dose before travelingKeeping your healthy habits going while awayI've learned a lot from my own travels—speaking at conferences, attending events, and doing advocacy work—and I've seen what works for both me and my patients who want to enjoy their trips without losing progress.We'll get into simple, practical strategies to stay consistent with nutrition, movement, medication, and mindset—the four pillars I use in obesity medicine. And as a bonus, I'll share key tips for anyone using Wegovy or Zepbound: how to pack them, store them, and stay on track with dosing while you're away.So if you've got a trip coming up and want to come home feeling good, energized, balanced, and still on track, this episode will walk you through exactly how to make that happen.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

n the News.. COVID-19 & T1D, Ozempic Pill Progress, Faster Insulin, “Beyond Misconceptions,” and More It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new study looks at the link between COVID-19 and very young children, Lilly moves ahead with their Ozempic oral pill, ultra-rapid insulin clears another hurdle, Beyond Type 1 launches a new campaign and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX https://www.scientificamerican.com/article/advances-in-type-1-diabetes-science-and-tech/ This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. XX More evidence linking COVID 19 to type 1 diabetes.. but still exactly why is a mystery. During the COVID-19 pandemic, there was an unexpected increase in the number of cases of type 1 diabetes in Sweden, particularly among children under 5 and young adult men. The infection accelerated the onset of diabetes among children between the ages of 5 and 9. The researchers looked at data from a 17-year period on the incidence of type 1 diabetes among all people under the age of 30 in Sweden. In addition, they compared the risk of developing diabetes among 720,000 individuals with positive COVID-19 tests against a control group of 3.5 million people. The findings are published in the journal Diabetologia. The number of diabetes cases increased by 12% in 2021 and 9% in 2022 compared with previous years. In 2023, the number of cases was back to a normal level. Despite this, the researchers cannot distinguish a clear connection between COVID-19 infection and diabetes, except for children between 5 and 9 years old. They had an increased risk of type 1 diabetes about one month after a COVID-19 infection even though their total risk did not increase. "However, it's clear that the COVID-19 vaccine can be ruled out as a cause of the increase in diabetes cases. The recommendation for the age group where we saw the strongest increase was not to get vaccinated. In addition, other studies on adults have shown that vaccination reduces the risk of developing type 1 diabetes after a COVID infection." https://medicalxpress.com/news/2025-10-diabetes-young-people-pandemic.html XX A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease—a serious and common complication of the condition, has shown promising results in a University of Bristol study. Findings from this new study, published in Molecular Therapy, demonstrated a 64% reduction in a damage indicator for kidney disease, paving the way for a potential new treatment. The study, explored the potential of delivering a protein called VEGF-C directly into kidney cells. Previous studies have shown VEGFC could protect against kidney disease as it helps keep blood vessels in the kidney filter healthy, repairing early signs of diabetes-related kidney damage. https://medicalxpress.com/news/2025-10-gene-therapy-kidney-disease-diabetes.html XX The FDA has agreed to consider Afrezza inhaled insulin for children and teens. The company said in August that it submitted a supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population and it's been assigned a decision deadline date of the end of May, 2026. Afrezza first recieved FDA approval for adults (age 18 and up) in June 2014 https://www.drugdeliverybusiness.com/fda-accepts-application-mannkind-inhaled-insulin-kids/ Update on inhaled insulin for kids.. in the open-label, randomized, phase 3 INHALE-1 clinical trial Afrezza demonstrated safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes (T1D and demonstrates comparable glycemic control to injected rapid-acting insulin. The INHALE-1 clinical trial assessed the safety and efficacy of Afrezza among children and adolescents with T1D, including a total of 230 patients aged 4 to 17 years. Researchers used basal injected insulin and randomly assigned inhaled insulin or rapid-acting analogue for meals, evaluating the change in hemoglobin A1c levels at 26 weeks. After completing 26 weeks of randomly assigned treatment with either Afrezza or rapid-acting insulin injections combined with basal insulin, participants continued receiving the inhaled insulin until week 52 for an extension phase to evaluate the safety and effectiveness of Afrezza with continued use.1,2 https://www.pharmacytimes.com/view/inhaled-insulin-demonstrates-comparable-safety-lung-function-and-efficacy-to-injectable-insulin-in-type-1-diabetes XX Eli Lilly released the results of two new Phase 3 trials of an experimental GLP-1 pill that the company says could become a “foundational treatment” for type 2 diabetes. The Indianapolis-based drugmaker plans to submit global regulatory applications for orforglipron in the treatment of type 2 diabetes next year. The company said it will seek approval of the drug as an obesity medication by the end of 2025. Lilly is trying to build on the success of its Mounjaro/Zepbound franchise by offering patients a pill instead of an injection. But the company is trailing behind rival Novo Nordisk in developing an oral alternative, and data released so far has raised some skepticism among investors. A study released in August showed that orforglipron could help patients lose an average of about 12% of their body weight. Wall Street had been expecting more; Lilly's injectable drug Zepbound produced weight loss of as much as 21%, and Novo Nordisk has achieved 15% weight loss percentages for both oral and injectable versions of its Wegovy medication.   https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins   XX XX UF Health Cancer Center researchers have found a surprising culprit behind common health problems such as obesity, diabetes and fatty liver disease: silent genetic glitches in the blood system that occur naturally as people age. The findings, published in the Journal of Clinical Investigation, mean that in the future, simple blood tests could be developed to identify people most at risk early on, helping prevent chronic illnesses and cancer through strategies like diet or lifestyle changes. As people age, stem cells in the bone marrow that produce blood cells gradually accumulate mutations in their DNA. Most mutations don't cause any issues, but sometimes blood stem cells with a mutation can start crowding out their peers. Called clonal hematopoiesis, this condition affects about 10% of older people and is associated with an increased risk of blood cancers like leukemia. It's also linked to a higher risk of obesity and diabetes. But the prevailing thinking was that obesity and related conditions promoted blood cell changes, not the other way around. The new study reverses that. The implications could be far-reaching, particularly as obesity has now overtaken smoking as the most significant and preventable risk factor for cancer. The team is studying how the mutations drive disease. Next, they plan to test how drugs like those commonly used to treat diabetes and new popular weight loss drugs might help reverse or prevent diseases caused by blood cell changes. https://medicalxpress.com/news/2025-10-hidden-blood-mutations-obesity-diabetes.html XX A new ultra rapid insulin continues to move forward. A phase 3 clinical trial of BioChaperone Lispro (liss-pro) conducted in China found it safe and effective compared with Humalog along with a significant reduction of the rise of blood glucose after a test meal.     These results complete and confirm the positive outcomes previously obtained with THDB0206 injection in people with Type 2 Diabetes It combines Adocia's proprietary BioChaperone® technology with insulin lispro, the active ingredient in the standard of care, Humalog® (Eli Lilly).   This innovative formulation acts significantly faster https://pharmatimes.com/news/ultra-rapid-insulin-shows-promise-in-phase-3-trial-for-type-1-diabetes/   Poor blood sugar control in adolescent patients with type 1 diabetes (T1D) may be associated with a higher risk of neuropathy in adulthood, according to recent research from the University of Michigan.1 The study included children diagnosed with T1D between 1990-1992 who were recruited into the Cognition and Longitudinal Assessment of Risk Factors over 30 Years cohort study in Australia. Investigators collected HbA1c from medical records, and microvascular complications were assessed through self-reports, clinical screenings, retinal photographs, and urinary albumin-creatinine testing.3   A total of 30 children were recruited from the original cohort with a mean diagnosis age of 2.9 years. After an average of 29.7 years (standard deviation [SD]: 3.9 years), 33% of participants (n = 13) developed neuropathy, 63% (n = 19) developed diabetes-related eye disease, and 10% (n = 3) developed neuropathy.3 Mean HbA1c estimates during adolescence (9% [74.9 mmol/mol]; 95% CI, 8.6-9.3 [70.5-78.1]) were substantially higher than childhood (8.2% [66.1 mmol/mol]; 95% CI, 7.8-8.5 [61.7-69.4]; P

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. This week's Your Friday Five is a little different — I'm answering a fan mail question about what to expect during the first month on Zepbound (tirzepatide). If you're just starting your GLP-1 journey, this episode is packed with quick, practical advice.In this episode, I cover:Why hydration is non-negotiable — and what to look for beyond just ounces.Protein goals and how to get your grams in even when your appetite drops.The role of fiber and how to ease your way in.Why experimenting with food textures, combinations, and timing is key early on.What to avoid to prevent nausea and other common side effects.Bonus insight: The first 2–3 months are a learning curve. Be patient with your body as it adjusts to the medication.Want a step-by-step, deeper dive? Check out my Mini Course: “Top 5 Mistakes People Make On a GLP-1” — complete with quick videos, live Q&As, bonus resources, and a supportive community. Get access HERE.And if you send in a fan mail question, make sure to include your email so we can follow up with more resources just for you.All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com ✨ Season 2 of Behind the Curtain is officially live! ✨ You can join the season on its own or take it a step further by opting into the live 21-Day Challenge with Dr. Rentea, running December 1–21—the perfect way to finish the year strong and head into the holidays with momentum.

Girl, I am so over these creepy AI “fitness” ads. Filters are bad enough but now we have actual robots preaching toxic diet culture BS! It's wild how far we've come from Photoshop and filters — now we're literally being sold body image standards that don't even exist.In this episode, I'm venting (because seriously, what is happening?!) but also unpacking what this means for those of us healing our relationship with our bodies. Because if you're already struggling to feel good in your skin, seeing these fake “fitfluencers” can seriously mess with your head.We'll talk about: 

In today's episode, I'm diving into everything you need to know about Zepbound (tirzepatide) — the newest obesity medication now available in Canada. I'll explain how this dual GIP/GLP-1 agonist works, how it's different from semaglutide (Ozempic/Wegovy), and who it may be helpful for.We'll talk about expected weight loss results, side effects, cost, and access, as well as one really important topic: how to protect your muscle and bone health while on these medications. Rapid weight loss can come with downsides — and I'll share what you can do to make sure your journey is sustainable and healthy.In this episode, I cover: → How tirzepatide works and what makes it unique → Expected weight loss and blood sugar improvements → Common side effects and safety considerations → Tirzepatide vs. semaglutide — what's the difference? → Cost, access, and insurance coverage in Canada → Why protein and strength training are essential during weight lossAs always, this podcast is for educational purposes only and not a substitute for personalized medical advice. Please talk to your doctor before making any changes to your treatment plan.Come connect with me on Instagram @sashahighmd, and don't forget to subscribe so you never miss a Monday episode! Other episodes: 108. All About Wegovy97. All About Mounjaro53. All About Ozempic145. Which one is better, Ozempic, Wegovy or Mounjaro?

In the last few years, GLP-1 weight-loss drugs like Ozempic and Zepbound have been radically reshaping the people's lives, changing appetites and health.But the drugs also have the power to affect other parts of consumers' lives, including their romantic relationships.Lisa Miller, who writes about health for The New York Times, tells the story of how these drugs upended one couple's marriage.Guest: Lisa Miller, a domestic correspondent for the Well section who writes about personal and cultural approaches to physical and mental health.Background reading: Weight-loss drugs have lesser-known side effects on relationships.Photo: Katherine Wolkoff for The New York TimesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

SUPPORT OUR WORK: OTPLinks.com

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________This isn't medical advice — always talk to your doctor before making any health decisions.Join us for an eye-opening conversation with Dr. Komal Patil-Sisodia, MD, a board-certified endocrinologist and obesity medicine specialist, as we uncover why healthcare access is so broken for patients seeking GLP-1 treatments and women's health support. From insurance denials to systemic inequities, Dr. Patil-Sisodia breaks down where the system fails—and how it could change for the better. We're also joined by Sabina, founder of GLP Winner, who shares her personal journey with obesity and her mission to help others find reliable information and providers for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound.Community Guest: Sabina | https://www.glpwinner.com/ - Helps compare GLP-1 provider options with transparent pricing, sourcing, and reviews.https://www.tiktok.com/@lawliepophttps://www.instagram.com/lawliepops/https://www.youtube.com/@lawliepophttps://x.com/lawliepopDoctor Guest: Dr Komal Patil-Sisodiahttps://www.instagram.com/drpatilsisodia?igsh=MWZyaHY2Mm1naGVwOA%3D%3D&utm_source=qrhttps://www.tiktok.com/@drpatilsisodia?_t=ZT-8zzn5gQRlvy&_r=1https://www.resetrecharge.com/https://www.eastsidemm.com/_______________________________________________________________Send us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

What does it really look like to set realistic expectations with weight loss medications like Zepbound and Wegovy?That's the focus of today's episode, and I'm joined by someone who knows this topic inside and out—Ana Reisdorf, a registered dietitian with over 15 years of experience. Ana is the founder of the GLP-1 Hub, where she provides resources, education, and support for people using GLP-1 medications. She also hosts a podcast dedicated to helping patients navigate the ups and downs of this journey.In our conversation, Ana shares why setting realistic expectations is so important—from understanding how dosing really works, to rethinking nutrition, and even reframing what progress looks like beyond the scale. She also points out common mistakes, like rushing to the highest dose too quickly or overly restricting food, and offers practical guidance on how to avoid them.We talk about:Why balanced nutrition is essential when taking weight loss medicationsWhy the right dose isn't always the highestManaging expectations and comparisons with weight loss medicationsRethinking “responders” and “non-responders” in weight loss medicationsProtein obsession vs. balanced nutritionThe role of fiber and balance in GLP-1 nutritionWhy GLP-1 medications aren't a shortcut—and how to use them effectivelyHow obesity and malnutrition can coexistAt the heart of this conversation is Ana's message that success with GLP-1s isn't just about losing weight—it's about improving health, nourishing the body, and creating a sustainable approach.Catch the full episode for more of Ana's insights and practical advice that can guide your own journey.Connect with Ana:Website: GLP-1 HubFacebook: GLP-1Hub Instagram: glp1hubYoutube:GLP-1 HubConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Are compounded GLP-1 meds like semaglutide and tirzepatide a smart shortcut or a risky gamble? In this episode, Dr. Lisa breaks down the real risks, pros & cons, and expert recommendations around using compounded versions of Wegovy, Ozempic, and Zepbound. If you're curious about affordable options for weight loss medications, or wondering if compounded GLP-1s are safe, this episode is for you.Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

I'm back from Disney and my brain feels like… pizza.

otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Join us for an eye-opening conversation with Dr. Komal Patil-Sisodia, MD, a board-certified endocrinologist and obesity medicine specialist, as we uncover why healthcare access is so broken for patients seeking GLP-1 treatments and women's health support. From insurance denials to systemic inequities, Dr. Patil-Sisodia breaks down where the system fails—and how it could change for the better. We're also joined by Sabina, founder of GLP Winner, who shares her personal journey with obesity and her mission to help others find reliable information and providers for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound.Community Guest: Sabina | https://www.glpwinner.com/ - Helps compare GLP-1 provider options with transparent pricing, sourcing, and reviews.https://www.tiktok.com/@lawliepophttps://www.instagram.com/lawliepops/https://www.youtube.com/@lawliepophttps://x.com/lawliepopDoctor Guest: Dr Komal Patil-Sisodiahttps://www.instagram.com/drpatilsisodia?igsh=MWZyaHY2Mm1naGVwOA%3D%3D&utm_source=qrhttps://www.tiktok.com/@drpatilsisodia?_t=ZT-8zzn5gQRlvy&_r=1https://www.resetrecharge.com/https://www.eastsidemm.com/______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 Send us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

This week on Fat Science, Dr. Emily Cooper, Andrea Taylor and Mark Wright take a hard look at the buzz around microdosing metabolic medications—from what “microdosing” actually means to the risks of following trends without clinical supervision. The team unpacks widespread misunderstandings about dosing for drugs like Ozempic, Zepbound, and low-dose naltrexone (LDN), explains why social media advice can be dangerous, and highlights just how unique every person's metabolic needs are. Dr. Cooper shares patient examples and lays out the science behind hormone regulation, medication resistance, and why skipping a full evaluation could backfire. We cover why glandular extracts and testosterone supplements can disrupt your body's natural balance and why trying to “trick” your metabolism with tiny doses can sometimes do more harm than good.Key Takeaways:Microdosing means doses far below anything supplied by drug companies—it's not the same as prescribing a lower dose within the normal range.Popular trends in LA and beyond push people toward self-experimentation, often with compounded drugs or unsupervised regimens.Taking metabolic drugs without a clinical need can weaken natural hormone production and create dependency—even with “natural” supplements.GLP-1s, GIPs, naltrexone, and testosterone all show very different outcomes depending on your genetics, history of dieting, childhood athletics, or use of other medications.More is not always better. Too high a dose can create medication resistance, while too low might “numb out” your hormone response.Professional evaluation, sleep, nutrition, and self-kindness remain the first line of defense for metabolic health, rather than skipping over those and heading straight to medication.Resources from the episode: Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.Check out our new website where you can ask a mailbag question. If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com.If you are a healthcare professional interested in Dr. Cooper's training course, go to FatSciencePodcast.com and click on the top right button for Provider Course.Connect with Dr. Emily Cooper on LinkedInConnect with Mark Wright on LinkedInConnect with Andrea Taylor on Instagram

Melt Away Fat! Never Diet Again!! The promises of “magic pills” that will lead to safe, effortless weight loss are everywhere. But while these mythical weight loss products may never exist…the FDA is getting ready to approve something extremely close. The news has been nearly impossible to miss…with a tidal wave of interest in medications that are revolutionizing an innovative approach to weight loss is swiftly evolving. Unlike past diet and weight loss trends, GLP-1 drugs are generating levels of enthusiasm that have rarely been seen. And honestly, there are few examples from history that have generated such impact. What once started as a lesser-known treatment (aiming to control blood glucose levels) of type-2 diabetics has turned Ozempic, Wegovy, Mounjaro, and Zepbound into household names, and brought us to the cusp of a health revolution. Furthermore, the next few days, months, and beyond, are shaping up to be a pivotal time for the GLP-1 landscape…mostly due to the FDA expectantly approving the first orally administered medication for chronic weight management (i.e. oral Wegovy semaglutide) sometime during this fourth quarter of 2025. Though, if this discovery has fueled an unprecedented surge in interest and demand for these current injectable peptides, why then are companies working so hard to make oral tablet forms of weight loss drugs that target the GLP-1 receptor? From a business perspective, there are some obvious advantages…such as oral tablet formulations tend to be cheaper and easier to manufacture and distribute than sterile injector pens. In fact, manufacturing complexity, both in terms of making the peptide active ingredients and producing the final injectors…significantly contributed to both Eli Lilly and Novo Nordisk struggling to supply surging demand for their products following approvals for weight loss indications. And from a patient perspective, oral weight loss pills are attractive for several reasons…most notably enhancing convenience for those who simply prefer pills to injections and making treatment accessible to those who are “extremely needle-phobic.” However, while tablet forms are generally more familiar and accessible to most individuals, the relative success of any oral drugs will likely depend on a combination of price, performance, and side-effect profiles. And although oral Wegovy is expected to be approved first, competition will quickly heat up from a myriad of biopharma companies, including Eli Lilly, Viking Therapeutics, Biomed, and Roche. In fact, Eli Lilly is expected to submit its application soon to the FDA for its once daily oral weight loss drug (with potential regulatory approval in 2026). Regardless, the demand for effective weight loss treatments is huge…and there's ample space in the market for a variety of complementary therapies. According to recent Goldman Sachs projections, the U.S. weight loss medication market will essentially triple to over $60 billion by 2030…with oral versions accounting for a quarter of that total market size. While oral weight loss drugs represent (in my opinion) one of the most significant new product cycles across the entire biopharma sector, there's no guarantee they make an immediate disruptive market impact or outcompete existing injectables long-term. And these will be margin accretive for the pharmaceutical industry's newest cash cow…even if this first wave isn't perfect, there will be a next wave of improvements, and then another new wave of improvements after that (if appropriate).

Dr. Fatima Cody Stanford, a leading specialist in obesity medicine and on GLP-1s joins Kelly to answer all of your most pressing questions about weight loss drugs (Ozempic, Wegovy, ZepBound), potential side effects and if it's possible to stop the meds and keep off the weight! She explains why GLP-1s don't work the same for every person, how to manage weight loss related hair loss, and if Ozempic face is a thing. Plus Dr. Stanford breakdowns if GLP-1 boosters are a gimmick. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

To read more of Derek's reporting on GLP-1 drugs, you can subscribe to his Substack here. GLP-1 drugs like Ozempic and Zepbound don't just help with Type 2 diabetes and weight loss. They seem to curb alcohol, cocaine, and tobacco use among addicts. In some studies, they prevent strokes, heart attacks, chronic kidney disease, sleep apnea, and Parkinson's disease. They're associated with a lower risk of several cancers, including pancreatic cancer and multiple myeloma. Arthritic patients on the drugs experienced relief from knee pain that was “on par with opioid drugs.” A small study found that they reduce migraine headaches by 50 percent. And emerging research suggests they might even slow the rate of memory loss among people diagnosed with Alzheimer's. Is all of this real? And if it's real, how is one drug doing so many different things? And if it is doing all those things, why shouldn't we be developing versions of the drug for just about everyone? Today we have two guests: David D'Alessio, chief of endocrinology and metabolism at the Duke University School of Medicine; and Randy Seeley, a professor of surgery, internal medicine, and nutritional sciences at the University of Michigan. We talk about how these drugs work—why they seem to do everything—and how our understanding of them could make them better, more effective, more broadly useful. If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guests: David D'Alessio and Randy Seeley Producer: Devon Baroldi Disclosure: Dr. Seeley has received research support from several pharmaceutical companies, including Eli Lilly, Diasome, and Amgen. Learn more about your ad choices. Visit podcastchoices.com/adchoices

People are losing their minds over Cracker Barrel, Eli Zaret joins us as the Detroit Tigers are on fire, Kirk Herbstreit cries again, Magnum P.I.G., Lil Naz X nuts, Jizzlaine Maxwell's DOJ interview, and Diamond David Lee Roth is always the showman. Kirk Herbstreit is a bumbling mess discussing Lee Coso retiring. Eli Zaret drops by to discuss Magnum P.I. Day at Comerica Park, the surging Detroit Tigers, Pitcher Drew Sommers debut, the Detroit Lions Super Bowl odds, Jason Benetti's many hats, the Lions 53-man roster, Shilo Sanders BLOWN OUT, CFB is back, more sports dildos and more. Warning: Fox 2 Stephanie Mead thirst trap. Cracker Barrel changed their logo and people are melting down. Steak ‘n Shake is on the attack. Michael Strahan gave the CEO time to do a commercial on Good Morning America. Marc loves the McDonaldland Meal… if the employee knows what it is. Halsey defends her movie Americana, which bombed at the box office. Lil Nas X has lost his mind and his clothes. SNL is ready to make some changes. Donald Trump's hands look old… cause he's old. Morgan Wallen is boycotting The Grammy's but won't say why. Jay-Z is really loaded. He the richest musician in history. Male cheerleaders are now getting backlash despite being around for quite a while. David Lee Roth is sounding awful lately. Like REALLY bad. Hold me closer, Tony Danza! Serena Williams is getting crap for taking the fat shot… and doing a commercial for Zepbound. Hey Amanda Bynes… why you look different? These brothers totally got it on. Travel with Livii has some pretty incredible travel requests. Jizzlaine Maxwell spills. Prince Andrew, Bill Clinton and Donald Trump are cleared of wrongdoing… yeah right. Donald Trump gets a victory over Letitia James. She'll appeal it. John Bolton was raided on Friday. Britney Spears remains crazy. Jenelle Evans claims to have made over $1.5M on OnlyFans. She's at odds with her son, Jace. Lil Tay calls out every woman over 25 who is not rich. Jeff Bezos wants his wife to be the next Bond Girl. If you'd like to help support the show… consider subscribing to our YouTube Channel, Facebook, Instagram and Twitter (Drew Lane, Marc Fellhauer, Trudi Daniels, Jim Bentley and BranDon).

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For people who had never been able to lose weight before, suddenly the numbers on the scale were plummeting. And everybody wanted to get their hands on them. Now, in most industries, if a product goes viral like this, it's a golden ticket. And thanks to government-granted monopolies designed to encourage innovation, the big drug companies behind these blockbuster injections are currently the only ones allowed to make them.In theory, anyway. But, what if that explosive demand backfired, opening the door to legal knock-offs? You've maybe seen them - copycats advertised as the same thing as Ozempic. So, what's the difference? And just how legal are they? On today's show - a drug that's changing people's lives is also challenging the traditional way we buy and sell medicine.This episode was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed. It was edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark is Planet Money's executive producer.Listen free at these links: Apple Podcasts, Spotify, the NPR app or anywhere you get podcasts.Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.Help support Planet Money and hear our bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.Music: Source Audio - “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy